Traditional neuroimaging modalities like Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) scans have been central to understanding Alzheimer’s disease, providing detailed structural and functional brain data. However, these methods remain costly, often inaccessible for routine or longitudinal use, and require complex infrastructure. In contrast, bNIRS measures dynamic changes in brain tissue by monitoring variations in light absorption, offering a noninvasive window to cerebral physiology with significantly less expense and greater portability.

What sets this new study apart is the use of broadband near-infrared spectroscopy that extends beyond tracking oxygenated and deoxygenated hemoglobin concentrations in the brain. By incorporating measures of the oxidation state of cytochrome c oxidase (oxCCO), a crucial mitochondrial enzyme tied to cellular energy metabolism, researchers gain access to a metabolic biomarker intimately linked to neuronal health. Cytochrome c oxidase participates in the electron transport chain within mitochondria, and its oxidation state reflects mitochondrial function, which is known to be compromised early in Alzheimer’s pathology.

The investigative team conducted a controlled pilot involving three distinct cohorts of elderly participants: cognitively healthy controls, individuals with mild cognitive impairment (MCI), and those diagnosed with early-stage Alzheimer’s dementia. Employing a simple visual stimulus—a checkerboard pattern—the researchers elicited measurable cerebral responses primarily from the visual cortex. The recorded signals included traditional hemodynamic parameters alongside oxCCO activity, captured synchronously using the wearable bNIRS system.

This study’s methodology showcases the nuances of brain response profiles in dementia. Key characteristics such as response amplitude and temporal delays displayed marked differences across the three groups. These findings underscore the potential of bNIRS not only to detect altered brain oxygenation but also to reveal metabolic deficits characteristic of neurodegeneration. Importantly, statistical models correlating these optical measurements with participants’ cognitive test scores underscored the critical role of oxCCO metrics. When oxCCO data were excluded, the predictive relationship between brain signals and cognition substantially weakened, highlighting the added diagnostic value of mitochondrial metabolic monitoring.

Mitochondrial dysfunction has long been implicated in Alzheimer’s disease, and cytochrome c oxidase oxidation state offers a direct, functional readout of this pathology at the cellular level. By advancing bNIRS technology to capture these signals noninvasively during functional tasks, the researchers have bridged a gap between molecular neuropathology and bedside diagnostics, all within a compact, wearable framework. This paradigm shift suggests that continuous monitoring of brain metabolism could become feasible even outside clinical environments.

The wearable nature of this technology means it can be deployed in patients’ homes or care facilities, democratizing access to brain health monitoring and providing clinicians with a valuable longitudinal dataset to assess disease progression or therapeutic response. Current imaging techniques rarely allow for such frequent and flexible usage, making bNIRS an attractive complement, especially for elderly populations that may find travel and hospital visits burdensome.

While the study’s sample size is limited, the robustness of its findings lays the groundwork for larger-scale trials. Future research will be needed to validate the reproducibility of bNIRS metrics and to refine analytical models that integrate metabolic and hemodynamic information for enhanced diagnostic accuracy. Moreover, the adaptability of broadband spectroscopy could facilitate the exploration of other neurological disorders characterized by mitochondrial dysfunction.

The prospects for integrating bNIRS with other neurophysiological and biochemical markers also open new avenues for comprehensive dementia profiling. By combining metabolic imaging with cognitive assessments, fluid biomarkers, and genetic risk factors, clinicians may soon adopt a multimodal framework capable of personalized diagnostic and therapeutic strategies, improving patient outcomes.

In summary, this pilot study heralds a new era in dementia diagnostics by demonstrating the feasibility and utility of broadband near-infrared spectroscopy for measuring brain metabolism and oxygenation noninvasively. The incorporation of mitochondrial biomarkers such as oxCCO within a wearable device underscores the potential for early detection and ongoing monitoring of Alzheimer’s disease in a more accessible, patient-friendly manner. Such technological innovation is poised to profoundly impact clinical neuroscience and pave the way for broader implementation of precision medicine in neurodegenerative conditions.

For those interested in exploring the detailed findings, the full study entitled “Mapping functional hemodynamic and metabolic responses to dementia: a broadband spectroscopy pilot study” is published in the Journal of Biomedical Optics. This seminal work exemplifies the integration of optical physics, neuroscience, and clinical innovation, providing a promising perspective on future diagnostics in brain health.

Subject of Research: Noninvasive neuromonitoring technology for early detection and monitoring of Alzheimer’s disease using broadband near-infrared spectroscopy.

Article Title: Mapping functional hemodynamic and metabolic responses to dementia: a broadband spectroscopy pilot study

News Publication Date: 3-Sep-2025

Web References:
https://www.spiedigitallibrary.org/journals/journal-of-biomedical-optics/volume-30/issue-S2/S23910/Mapping-functional-hemodynamic-and-metabolic-responses-to-dementia–a/10.1117/1.JBO.30.S2.S23910.full

References:
Acharya, D., et al. (2025). Mapping functional hemodynamic and metabolic responses to dementia: a broadband spectroscopy pilot study. Journal of Biomedical Optics, 30(S2), S23909. https://doi.org/10.1117/1.JBO.30.S2.S23910

Image Credits:
Image courtesy of D. Acharya et al. (University of Cambridge).

Keywords

Neuroscience, Dementia, Cognitive disorders, Diagnostic imaging, Optics

Historically, Alzheimer’s disease research has concentrated on individuals aged 50 and above, largely due to the late onset of clinical symptoms such as memory loss and cognitive decline. However, Allison Aiello, PhD, who spearheaded the investigation, highlights that cognitive differences linked to Alzheimer’s risk factors manifest decades earlier. This insight offers a paradigm shift by revealing a protracted preclinical phase during which intervention could potentially alter the disease trajectory. Her work fundamentally redefines the window of opportunity for clinical and public health interventions aimed at reducing the burden of this neurodegenerative illness.

Central to the study’s methodology was the utilization of the Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) score. This composite metric integrates well-established risk variables encompassing demographic factors such as age, sex, and education, alongside modifiable biological measures including systolic blood pressure, body mass index, cholesterol levels, physical activity, and the genetic predisposition conferred by the apolipoprotein E ε4 allele (APOE ε4). The CAIDE score has long been validated as a predictive tool for Alzheimer’s disease risk, but its application to a younger cohort is innovative and elucidates the temporal evolution of cognitive risk factors.

The research leveraged longitudinal data from Waves IV and V of the National Longitudinal Study of Adolescent to Adult Health (Add Health), which has meticulously tracked a nationally representative sample of adolescents from 1994-1995 through subsequent adult follow-ups. Wave IV data encompassed nearly 11,500 individuals between the ages of 24 and 34, with a balanced gender distribution and a predominantly White demographic. Participants underwent comprehensive in-home assessments including cognitive testing, physical examinations, and blood sample collection, enabling a multifaceted characterization of their health and genetic risk profiles.

Wave V continued this rigorous assessment into later adulthood, examining roughly 1,112 individuals aged 34 to 44 through both in-person and remote surveys. These participants completed cognitive batteries measuring immediate and delayed word recall along with backward digit span tasks, all sensitive indicators of working memory and executive function. Genetic analyses were performed on a subset, further enriching the dataset. Crucially, cognitive performance metrics were statistically linked to CAIDE scores in a subset of 529 individuals, establishing a robust correlative framework that connects early adulthood cardiovascular and genetic risk factors to tangible cognitive outcomes.

One of the study’s pivotal findings is the identification of strong correlations between cardiovascular health indices and cognitive function well before the previously accepted midlife threshold of 50 years. These findings illuminate the subtle yet cumulative impact of vascular risk factors—such as hypertension, dyslipidemia, and obesity—on neural integrity and cognitive resilience. The results align with emerging literature asserting the cerebrovascular contributions to neurodegenerative pathologies, implicating hypertension and metabolic syndrome as accelerators of neuropathological decline.

In parallel, the study delved deeply into biological markers recognized as hallmarks of Alzheimer’s pathology, specifically the amyloid (A), tau (T), and neurodegeneration (N) biomarkers, collectively dubbed the ATN framework. These biomarkers dominate contemporary research as reliable indicators of the disease’s neuropathological progression. Intriguingly, the presence and associations of ATN markers with cognitive function were detectable in participants well before the anticipated middle-age risk phase, suggesting that the molecular underpinnings of Alzheimer’s can be active for decades without overt clinical presentation.

The immune system’s role in Alzheimer’s disease etiology also garnered attention in this comprehensive analysis. Immune and inflammatory biomarkers, increasingly recognized as critical contributors to neurodegeneration, displayed significant associations with cognitive performance in these younger adults. This supports the hypothesis that chronic systemic inflammation may exacerbate neural vulnerability and precipitate cognitive decline. These immune-related pathways could offer novel targets for early therapeutic modulation designed to stave off or mitigate the disease process.

On the genetic front, the APOE ε4 allele—although a well-known and potent risk factor for late-onset Alzheimer’s—did not exhibit a measurable impact on cognitive function within this younger cohort. This unexpected finding suggests that the genetic risk conferred by APOE ε4 might exert its influence primarily during older adulthood or act synergistically with aging-related biological changes. It underscores a complex temporal and mechanistic landscape where genetic susceptibilities unfold in interaction with environmental and physiological factors over decades.

Taken together, these findings advocate for a life-course approach to Alzheimer’s disease prevention, emphasizing the detection and management of cardiovascular, immune, and molecular risk factors beginning in early adulthood. The decades-long latency before clinical symptoms emerge offers a potentially transformative interval for interventions that could delay or prevent the eventual progression to cognitive impairment and dementia. This aligns with the urgent public health mandate to address Alzheimer’s as a chronic disease with extensive societal and economic consequences.

Dr. Aiello stresses that the identification of these early risk signals shifts the landscape for clinicians and researchers alike. Recognizing that pathological processes begin so early necessitates reevaluation of screening and monitoring practices. Public health policies must evolve to incorporate earlier and more personalized risk assessments, alongside educational campaigns that encourage proactive management of cardiovascular health and lifestyle factors from a much younger age.

The rigor and scale of this study are notable for their integration of longitudinal data, multi-modal biomarkers, and comprehensive cognitive evaluations in a large, representative U.S. sample. The extensive collaborations among experts from Columbia University and the University of North Carolina at Chapel Hill facilitated a multidisciplinary approach that enhances the credibility and impact of the findings. Furthermore, the study received robust support from significant federal funding sources, underscoring the priority placed on understanding Alzheimer’s disease from a public health perspective.

As the prevalence of Alzheimer’s disease continues to rise globally with aging populations, these insights highlight an unprecedented opportunity. Investing in early detection and intervention strategies that consider cardiovascular, immunological, and molecular factors could substantially alter the course of the disease epidemic. The study’s implications extend beyond clinical domains into policy-making, health education, and future research directions aiming to unravel the complex pathophysiology of Alzheimer’s disease.

In conclusion, this pioneering research redefines our understanding of Alzheimer’s disease risk by demonstrating that key biological and cardiovascular risk factors exert measurable effects on cognition decades before clinical symptoms appear. The findings advocate for an early, proactive approach to prevention, leveraging biomarkers and risk scores to guide interventions that could ultimately reduce the global burden of dementia. Columbia University’s continued commitment to advancing public health knowledge reinforces the vital role of interdisciplinary research in tackling one of the most pressing health challenges of our time.

Subject of Research: Alzheimer’s disease risk factors and early-life cognitive function

Article Title: Risk factors for Alzheimer’s disease and cognitive function before middle age in a U.S. representative population-based study

News Publication Date: April 21, 2025

Web References:
https://www.sciencedirect.com/science/article/pii/S2667193X25000973
http://dx.doi.org/10.1016/j.lana.2025.101087

References: Study supported by Add Health (grant P01HD31921), Eunice Kennedy Shriver National Institute of Child Health and Human Development (P2CHD050924), National Institute on Aging (grants U01AG071448, U01AG071450, R01AG057800, P30AG066615), and T32HD091058.

Keywords: Alzheimer disease, risk factors, biomarkers, cardiovascular disease, epidemiology, public health, neurodegenerative diseases